- Aptar Pharma and COVIRIX Medical are collaborating under a Letter of Intent.
- The focus is on adapting Aptar's DPI platform for COVIRIX's antiviral compound.
- The project targets respiratory viruses like Covid-19, influenza, and RSV.
- The collaboration is in the feasibility study phase, with no guaranteed product development.
Collaboration Overview
Aptar Pharma and COVIRIX Medical have entered a technical collaboration under a Letter of Intent. The partnership aims to explore the feasibility of using Aptar's dry powder inhalation (DPI) platform for delivering COVIRIX's antiviral compound.
Project Focus
The collaboration will conduct a feasibility study to adapt Aptar's DPI technology for COVIRIX's antiviral compound. The goal is to develop an integrated product for potential use against respiratory viruses such as Covid-19, seasonal influenza, avian influenza, and RSV.
Antiviral Portfolio
COVIRIX Medical reports positive virology results for its antiviral portfolio against key pandemic-potential viruses. The company is advancing its patented broad-spectrum antiviral compounds for inhaled delivery, aiming for high local efficacy and minimal systemic side effects.
Technology and Services
Aptar Pharma's advanced DPI technology, Orbital™, is a novel device designed to deliver high payload powder drug formulations directly to the lungs. The collaboration will also leverage Aptar Pharma's range of services, including formulation development via Nanopharm, to facilitate and accelerate the development of the finished drug product.
Current Status
The collaboration is focused on feasibility work and does not guarantee the development or commercialization of any product.
